News

The STEM (SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer) trial is investigating SFX-01 in combination with different hormone-based therapies in 60 metastatic breast cancer patients

The trial’s original objective was the effect on progression-free survival (PFS) but the company has now added overall survival (OS), both for the combination and durvalumab monotherapy. The

The ‘167 patent has a priority date as far back as 2001, as well as additional priority in 2005. The complaint was filed in the United States District Court

The Company has also entered into a grant-funded collaboration with Solentim, the developer of the Cell Metric and dedicated instrumentation for cell line development, to establish automated approaches for

Sulfatinib is an oral, novel angio-immunokinase inhibitor that selectively targets vascular endothelial growth factor receptor (“VEGFR”), fibroblast growth factor receptor (“FGFR”) and colony-stimulating factor-1 receptor (“CSF-1R”), three key

Founded in 2016, Wren was spun out of the University of Cambridge and Lund University, Sweden. It is engaged in the drug discovery and development for protein misfolding diseases,

The SMC approved the use of Elbasvir-grazoprevir, known as Zepatier, saying it is a combination of two medicines that inhibit the replication of the Hepatitis C virus and

The Company intends to complete a reduction in force affecting 25 employees, including Jon Congleton, President and Chief Executive Officer, and David Rodman, M.D., Chief Medical Officer and

Baricitinib is being co-developed by Eli Lilly and Company and Incyte under an exclusive global license and collaboration agreement signed in December 2009. It is intended to be taken orally